反应详情

Tert-butyl 3-[(3-{5-[3-(methoxymethyl)-4-(2-methylpiperidin-1-yl)phenyl]-1,2,4-oxadiazol-3-yl}benzyl)oxy]propanoate was prepared following the general procedure 3 starting from Intermediate 2 and Intermediate 20. It was hydrolyzed following general procedure 8 to afford the title compound as a pale yellow powder. 1H NMR (DMSO-d6, 300 MHz) δ 8.19 (m, 1H), 8.06 (m, 3H), 7.57 (m, 2H), 7.39 (m, 1H), 4.60 (s, 2H), 4.57 (m, 2H), 3.70 (t, J=6.2 Hz, 2H), 3.42 (s, 3H), 3.24 (m, 1H), 3.03 (m, 1H), 2.63 (m, 1H), 2.54 (t, J=6.2 Hz, 2H), 1.85-1.30 (m, 6H), 0.86 (d, J=6.1 Hz, 3H). LC/MS (Method B): 466.4 (M+H)+, 464.4 (M−H)−. HPLC (Method A) Rt 3.30 min (Purity: 98.3%).